Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats
Dyskinesia affects the majority of levodopa-treated parkinsonian patients within 5–10 years of treatment with levodopa. Clinical and preclinical observations suggest that an increase in serotoninergic transmission can contribute to the appearance of dyskinesias. It is thus conceivable that a modulation of synaptic dopamine (DA) levels induced by the inhibition of serotonin (5-HT) release, as a consequence of 5-HT1A agonists administration, might alleviate dyskinesias.
Since 5-HT1A receptors are expressed in the subthalamic nucleus (STN), the aim of the present study was to assess the effect of the intrasubthalamic administration of sarizotan, a compound with full 5-HT1A agonist properties, on levodopa-induced dyskinesias in the 6-hydroxydopamine (6-OHDA) model of parkinsonism.
Materials and methods
Male Sprague–Dawley rats received a unilateral 6-OHDA administration in the nigrostriatal pathway. A test of apomorphine was performed to evaluate dopamine depletion. One week later, a cannula was implanted in the STN. Animals were treated with levodopa (6 mg/kg, i.p., twice at day) for 22 consecutive days. On day 23, several doses (1 ng, 10 ng, or 1 μg) of sarizotan were administered through the cannula to the STN. The higher doses of sarizotan effectively attenuated all levodopa-induced dyskinesias including axial, limb, and orolingual subtypes.
These results suggest that the STN is a target structure for the antidyskinetic action of sarizotan and indicate that drug-mediated modulation of STN activity may be an alternative option for the treatment of levodopa-induced dyskinesias in Parkinson’s disease.
KeywordsParkinson’s disease Dopamine Levodopa Dyskinesia Subthalamic nucleus Serotonin Sarizotan
This research was supported by an unrestricted grant from Merck KGaA (Darmstadt, Germany). Esther Aguilar is partially financed by the program: Ayudas para Contratos de Apoyo a la Investigación en el Sistema Nacional de Salud from the Ministerio de Sanidad y Consumo of the Spanish Government.
- Bartoszyk GD (2006) Mechanism of antidyskinetic action of sarizotan: a basal ganglia circuitry hypothesis. Mov Disord 21(Suppl 15):S572–573Google Scholar
- Bartoszyk GD, Kuzhikandathil EV (2005) Receptor pharmacology of the antidyskinetic drug sarizotan. Parkinsonism Relat Disord 11(Suppl 2):241Google Scholar
- Bartoszyk GD, van den Buuse M, Gerlach M, Riederer P (2006) Mechanism of the antidyskinetic efficacy of sarizotan in hemiparkinsonian rats. Mov Disord 21(Suppl 15):S495Google Scholar
- Bedard PJ, Gregoire L, Samadi P, Bartoszyk GD, Di Paolo T (2006) Sarizotan reduces dyskinesia and maintains antiparkinsonian efficacy of levodopa in MPTP monkeys. Soc Neurosci Abstract no. 175.10Google Scholar
- Carlsson T, Carta M, Winkler C, Björklund A, Kirik D (2007) Serotonin neuron transplants exacerbate-dopa-induced dyskinesias in a rat model of Parkinson’s disease. Neurobiol Dis 27:8011–8022Google Scholar
- Dupre KB, Eskow KL, Steiniger A, Kiloueva A, Negron GE, Lormand L, Park JY, Bishop C (2008) Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on l-dopa-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat. Psychopharmacology 199:99–108PubMedCrossRefGoogle Scholar
- Gerlach M, Bartoszyk GD, van den Buuse M, Schwarz J, Riederer P (2006a) Antidyskinetic efficacy of sarizotan. Mov Disord 21(Suppl. 13):S71–72Google Scholar
- Gerlach M, van den Buuse M, Bartoszyk G, Riederer P (2006b) Mechanism of the antidyskinetic efficacy of sarizotan in hemiparkinsonian rats. Int J Neuropsychopharmacol 9(Suppl 1):S121Google Scholar
- Gobert A, Lejeune F, Rivet JM, Audinot V, Newman-Tancredi A, Millan MJ (1995) Modulation of the activity of central serotoninergic neurons by novel serotonin 1A receptor agonists and antagonists: a comparison to adrenergic and dopaminergic neurons in rats. J Pharmacol Exp Ther 273:1032–1046PubMedGoogle Scholar
- Kannari K, Yamato H, Shen H, Tomiyama M, Suda T, Matsunaga M (2001) Activation of 5-HT1A, but not 5-HT1B receptors attenuates an increase in extracellular dopamine derived from exogenously administered l-dopa in the striatum with nigrostriatal denervation. J Neurochem 76:1346–1353PubMedCrossRefGoogle Scholar
- Matsumara M, Kojima J, Gardiner TW, Hikosaka O (1992) Visual and oculomotor functions of monkey subthalamic nucleus. J Neurophysiol 67:1615–1632Google Scholar
- Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. Academic, New YorkGoogle Scholar